78 results about "Hematologic disease" patented technology

The present invention refers to the use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, which have important activities in increasing the gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-α levels and an exogenous source of nitric oxide. More particularly, the present invention describes the use of such phthalimide and/or sulphonamide derivatives for the treatment of sickle-cell disease. The invention also has as a novel characteristic the disclosure of new functionalized phthalimide derivatives designed from the prototypes thalidomide and hydroxyurea, and designed rationally through the strategy of molecular hybridization for the treatment of said diseases. The invention still discloses a new method for obtaining a specific sulphonamide derivative which can be used in the preparation of a drug for the treatment of diseases which require reducing the levels of the TNF-α factor and an exogenous source of nitric oxide.

The present invention provides a humanized anti-human CD34 antibody and the preparation method thereof. The humanized anti-human CD34 antibody retains the affinity and specificity of its original murine-derived antibody. The antibody can be conjugated with magnetic nano materials to prepare immunomagnetic beads to screen marrow hemopoietic stem cells. It can effectively reduce the incidence rate of HAMA and improve the security of clinical transplantation of hemopoietic stem cells and can be used in treatment of certain malignant hematologic diseases and solid tumors.

Methods, systems, and computer readable media are provided for processing microscopic images of a biological sample from a patient. One or more images of a blood sample from a microscope is obtained, each image comprising a plurality of different types of cells. The one or more images are processed by a machine learning system to classify individual cells into one of a plurality of cell categories. The cells in each cell category are analyzed to determine characteristics of the respective cell category. A diagnosis or list of possible diagnosis are determined based on the classification and characteristics of the cells for the patient in an automated manner.

The invention provides a blood virus RAN protective agent and a blood sampling tube. The blood virus RAN protective agent is prepared by dissolving the following components in DEPC (diethyl pyrocarbonate) solution 100-500mg/ml glycine, 1-5mg/ml aprotinin, 1-5mg/ml wortmannin, 10-40mg/ml glutathione, 100-500mg/ml sodium thiocyanate, 1-3mg/ml anticoagulant and 5-20mg/ml membrane protective agent. The blood virus RAN protective agent provided by the invention is capable of supplying long-term protection to virus RNA in blood under room temperature, preventing degradation and pollution of virus RNA and effectively guaranteeing accuracy and validity of blood sample.

Medium-chain length fatty alcohols such as octanol, decanol, dodecanol, or analogues thereof can be used as a stimulator of hematopoiesis, hematopoietic stem cell proliferation, and/or proliferation of one or more of the progenitors of red or white blood cells (e.g., erythrocyte, leukocyte, neutrophil, granulocyte, megakaryocyte, or any combination thereof). It also relates to the treatment of myelosuppression; in particular, this includes the treatment of anemia and/or neutropenia associated with chemotherapy and/or radiotherapy. Moreover, anemia arising from chronic renal failure or treatment of HIV-infected patients with AZT (zidovudine), or other inhibitors of reverse transcriptase, can be treated. Furthermore, neutropenia arising from infections, hematologic diseases, or nutritional deficiencies can be treated. It also relates to reducing drug toxicity and enhancing drug efficiency.

The present invention relates to pathogen inactivator composition for blood or blood component for clinical transfusion and its compounding process. The blood pathogen inactivator consists of photosensitizer capable of inactivating blood or blood component and supplementary material for venoclysis in the weight of 2-10 times that of the photosensitizer. The pathogen inactivator in the pathogen inactivator composition is solid and has the stability of the pathogen inactivating photosensitizer maintained. The pathogen inactivator and relevant supplementary material is prepared through high temperature pyrogen eliminating and abacterial filtering, and may be used in the photochemical pathogen inactivation of blood or blood component.

Preparation of an orally administrable pharmaceutical composition containing traditional Chinese medicine for hematologic diseases is disclosed. The pharmaceutical composition is for immunotherapy and is made from natural, non-toxic medicinal materials through extraction and other preparing processes. The pharmaceutical composition is helpful to prevent, mitigate and cure cancers.

A reconstituted polypeptide characterized by inducing apoptosis in nuclear blood cells having integrin associated protein (IAP) without causing the agglutination of erythrocytes. This reconstituted polypeptide contains at least two H chain V domains and at least two L chain V domains of a monoclonal antibody which induces apoptosis in nuclear blood cells having IAP. This reconstituted polypeptide is useful as a remedy for blood diseases such as leukemia.

The invention discloses a blood disease leukocyte scatter diagram similarity analysis method based on structural analysis, and belongs to the technical field of blood cell classification. The method comprises the following steps: extracting cell counting results and leukocyte scatter diagrams of various blood diseases detected by a hematology analyzer, carrying out artificial staining microscopicexamination to confirm the types of the blood diseases, carrying out classified storage according to the types of the blood diseases, and constructing a training set; comparing the leukocyte scatter diagrams of each category in the training set through a structural similarity analysis algorithm to obtain similarity; analyzing the similarity to obtain a characteristic leukocyte scatter diagram anda similarity range of each type of blood diseases, and taking the characteristic leukocyte scatter diagram as an original image; the to-be-detected image detected by the hematology analyzer is compared through the original image and the similarity range of each type of blood diseases, automatic classification of images collected by the hematology analyzer is achieved, and the effect of quickly andaccurately analyzing and classifying leukocyte scatter diagrams of the blood diseases is achieved.

The invention relates to a hot-drinking plaster preparation used for curing blood platelet countpenia of endogenous heat due to yin deficiency type, which comprises medicinal materials such as India madder roots, rehmannia root, common anemarrhena rhizome, amur corktree bark, glossy privet fruit, eclipta, red paeony root, charred radix scutellariae, fresh oyster, couchgrass roots, lotus rhizome node, ass-hide glue, tortoise plastron, common yam rhizome, etc. The hot-drinking plaster preparation of the invention used for preventing and curing blood platelet countpenia of endogenous heat due to yin deficiency type and has the advantages and effects of rich raw materials, easy preparation, convenient dosing, strong targeting force and guiding force, good treatment effect, no toxic and side effect, has one hundred percent of efficiency for clinically curing the blood platelet countpenia of endogenous heat due to yin deficiency type, etc., which fills the blank of a task field of processing the hot-drinking plaster preparation with the treatment functions of nourishing the kidney, producing medulla, nourishing yin, clearing away the lung-heat, eliminating pathogenic heat from the blood, activating blood circulation to dissipate blood stasis, dispelling heat from blood to stop bleeding, nourishing yin and suppressing hyperactive yang and proliferating blood platelet and greatly develops research on medicine culture of food therapy of human hematologic disease nowadays.

The invention relates to a medicament for treating hematuria and a preparation method thereof. The medicament is prepared from raw yam, raw fossil fragments, raw oyster, cuttlebone, madder, radices paeoniae alba, the root of Chinese pulsatilla, donkey-hide gelatin and gentian according to certain parts by weight through compatibility. The Chinese medicinal composition disclosed by the invention can replenish and nourish blood, clear away heat and remove toxicity, resist bacteria and inflammation, moisturize dryness and stop bleeding, promote blood coagulation and improve compactness of the vascular wall and has a practical curative effect of treating hematuria caused by tumors of the urinary system, prostatitis, acute cystitis, acute nephritis and kidney or ureteral calculus and particularly hematuria caused by blood diseases. Moreover, the medicament has no toxic or side effects.

The invention relates to the field of biotechnology. Hematopoietic stem cell transplantation is a unique way of curing malignant hematologic diseases, but the complications in the hematopoietic stem cell transplantation process are still key factors causing death of the patient, and the most prominent is graft-versus-host disease (FVHD). How to prevent and treat the GVHD is a severe challenge to hematopoietic stem cell transplantation. The invention provides an adenovirus vector carrying inducible co-stimulater (ICOS) gene, and a construction method for the adenovirus vector. After the adenovirus vector transfects mesenchymal stem cells (MSCs), an aim of preventing and treating the GVHD is fulfilled by a method of combining the effect of the ICOS in the T lymphocyte activating process and the effect of the MSCs in the immune adjusting process.

New monoclonal antibodies for use in pre-treatments prior to stem cell transplantations are disclosed. The antibodies may be used to kill malignant cells and/or stem cells prior to stem cell transplantation. The antibodies can be used for treating hematologic diseases and hematological malignancies, such as leukemia and MDS. The antibodies of the invention might be multi- or bi-specific, such as BiTEs.

The invention discloses a device for detecting a blood disease fusion gene. The device comprises a sequencing module used for obtaining sequencing data of a tumor sample through next-generation sequencing; a data preprocessing module used for preprocessing the sequencing data obtained in the sequencing module; a candidate k-mers identification module used for identifying candidate k-mers possiblycomprising breakpoints in the sequencing data processed by the data preprocessing module; a local assembly comparison recognition fusion mode module used for extracting reads where a candidate k-mersset of the tumor sample is located and paired reads, and carrying out local assembly to obtain contigs; a fusion gene credibility prediction module used for predicting the fusion gene credibility; anda fusion result annotation module used for annotating the breakpoints obtained in the fusion gene credibility prediction module. By applying the technical scheme provided by the invention, various fusion variation types of multiple genes can be accurately identified.

The invention discloses a molecular marker and an application thereof in detection of vascular immunoblastic T cell lymphoma, and belongs to the technical field related to blood disease detection. According to the application, a combination of multiple markers disclosed by the invention is applied to flow cytometry detection of vascular immunoblastic T cell lymphoma and/or monitoring of minimal residual focuses. The molecular marker disclosed by the invention can be widely applied to living cell samples such as bone marrow, peripheral blood, lymph nodes, puncture objects, skin tissues, pleural effusion, peritoneal effusion and the like of a patient, the combination of various markers is effectively arranged, abnormal cells of AITL can be quickly screened out in an early stage, the sensitivity and specificity to tissue samples reach 100%, the use amount of cells is small, and operation is rapid, simple and convenient. Meanwhile, for a patient subjected to chimeric antigen receptor T cell treatment, the composition disclosed by the invention can also be used for evaluating the immunofluorescence intensity of an antigen target spot, the immunofluorescence intensity is an indispensable part in cell treatment, and subsequent residue monitoring is not influenced by treatment.